Skip to content


Volume 3 Supplement 1


  • Poster presentation
  • Open Access

Comparison of macroscopic abnormalities in patients receiving routine pantoprazole when compared to placebo

  • 1,
  • 2,
  • 1, 2,
  • 1,
  • 1,
  • 1,
  • 1, 2,
  • 3, 4 and
  • 1, 2
Intensive Care Medicine Experimental20153 (Suppl 1) :A980

  • Published:


  • Placebo
  • Duodenal Ulcer
  • Enteral Nutrition
  • Pantoprazole
  • Stress Ulcer Prophylaxis


Gastrointestinal (GI) mucosal abnormalities have been observed within 24 h of admission to ICU and are thought to represent a 'stress' response. While acid-suppressive drugs are frequently administered to ICU patients, for stress ulcer prophylaxis, there are sparse data to support its efficacy.


To compare the presence of macroscopic mucosal abnormalities during upper GI endoscopy in mechanically ventilated, critically ill patients randomised to receive pantoprazole or placebo.


Ten patients were evaluated (6 M:4 F; age 41.7 ± 4.3 y; admission APACHE II score 19.4 ± 1.9; pantoprazole n = 4, and placebo n = 6) from a larger prospective study, in which 209 mechanically ventilated patients were randomised to receive IV pantoprazole (40 mg) or placebo in a double-blind fashion. Patients who received ≥ 5 doses of pantoprazole/placebo (80 patients in total) were eligible for the endoscopy sub-study. Written and informed consent was obtained from the patient's next of kin. The presence of one or more macroscopic abnormalities (erythema or oedema, erosions, ulcerations and naso-gastric tube lesions) and GI bleeding (petechial or sub-mucosal bleeding, haematoma, coffee-ground material and frank blood) were assessed at endoscopy by a single experienced gastroenterologist who was blinded to the intervention. Data are mean ± SEM or median (IQR) and were compared using Mann-Whitney U tests or chi-squared tests as appropriate.


Patients had received pantoprazole 8.8 ± 0.3 doses or placebo 10.7 ± 1.1 doses prior to endoscopy (p = 0.21). One patient in the pantoprazole group was also receiving corticosteroids, and another received regular non-steroidal anti-inflammatory drug therapy. Patient's haemoglobin on the day of endoscopy were similar (pantoprazole: 89.8 ± 6.0 vs. placebo: 83.7 ± 3.7g/dL; p = 0.52), one patient (receiving pantoprazole) had received a blood transfusion prior to endoscopy. All patients were receiving enteral nutrition prior to endoscopy. Upper GI mucosal abnormalities were observed in a total of 3 patients treated with pantoprazole (75%) and 4 patients treated with placebo (66%), without a difference between treatments (p = 0.78). Observed abnormalities included

(i) erythema/oedema/erosions (pantoprazole: 2 patients vs. placebo: 2 patients)

(ii) naso-gastric tube-related lesions (3 vs. 2),

(iii) petechial or sub-mucosal bleeding (0 vs. 2), and (iv) duodenal ulcer, (0 vs. 1); the latter was not associated with bleeding but the patient was switched to open label pantoprazole.


Upper GI mucosal abnormalities may occur frequently in mechanically ventilated patients. However, in this small cohort, the prevalence of mucosal abnormalities does not appear to be substantially reduced by administration of prophylactic pantoprazole.

Grant Acknowledgment

This project was funded by a Royal Adelaide Hospital Research Foundation project grant.

Authors’ Affiliations

Intensive Care Unit, Royal Adelaide Hospital, Adelaide, Australia
Discipline of Acute Care Medicine, The University of Adelaide, Adelaide, Australia
Discipline of Medicine, The University of Adelaide, Adelaide, Australia
Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia


© Summers et al.; 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.